Join to view full profile
2700 Sheridan StreetSuite MHollywood, FL 33021
Phone+1 754-236-4320
Fax+1 954-432-6266
Dr. Wiznitzer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1978 - 1981- Northwestern University The Feinberg School of MedicineClass of 1978
Certifications & Licensure
FL State Medical License 2002 - 2028
IL State Medical License 1979 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
Publications & Presentations
PubMed
- 396 citationsAMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.James B. Bussel, David J. Kuter, James N. George, Robert McMillan, Louis M. Aledort
The New England Journal of Medicine. 2006-10-19 - 8 citationsA phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancerJanet S. Rader, Daniel L. Clarke-Pearson, Malcolm J. Moore, Linda F. Carson, R. Holloway
Gynecologic Oncology. 2003-11-01 - 433 citationsBlinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients...Frankie A. Holmes, Joyce O'Shaughnessy, Svetislava J. Vukelja, Stephen E. Jones, J. Shogan
Journal of Clinical Oncology. 2002-02-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
